The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Autogel     10-(4-aminobutyl)-N-(1- aminocarbonyl-2...

Synonyms: Somatulin, Ipstyl, Lanreotida, Lanreotide, Somatuline, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Autogel


Psychiatry related information on Autogel


High impact information on Autogel

  • However, novel analogues from both groups were 30-40% more potent than octreotide and lanreotide in suppressing GH (P < 0.05) [5].
  • IGFBP-1 increased (P < .05) in both groups postoperatively, but levels in lanreotide-treated patients exceeded (P < .05) those of placebo-treated patients [6].
  • Lanreotide treatment resulted in minor reductions (P < .05) in free and total IGF-II and IGFBP-3, whereas insulin was unaltered [6].
  • Half of the patients received continuous subcutaneous infusion of the somatostatin analogue lanreotide from the day before (baseline) and for 4 days after PTCA [6].
  • Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors [7]?

Chemical compound and disease context of Autogel


Biological context of Autogel


Anatomical context of Autogel

  • The results suggest that growth factors are the main effector molecules leading to myocyte proliferation in allograft arteriosclerosis and that allograft arteriosclerosis (chronic rejection) may be specifically inhibited by lanreotide administration [17].
  • In contrast, the same dose of lanreotide given as a bolus injection only temporarily blunted postprandial hyperemia (mean AUC(ab) for superior mesenteric artery, 251.4 L/min.min, P <.001; mean AUC(ab) for portal vein, 194.95 L/min.min, P <.001), and subjects had significantly more side effects [16].
  • Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma [18].
  • CONCLUSION: Intravenous administration of lanreotide at rates applied in this study was able to significantly inhibit intragastric acid secretion and postprandial gallbladder contraction; under these conditions few untoward effects were noted [13].
  • Cultured tumor cells were treated with SRIH, lanreotide (BIM-23014), or SRIH analogs selective for SSTR2 (BIM-23120), SSTR5 (BIM-23206), or SSTR1 (BIM-23926) [19].

Associations of Autogel with other chemical compounds


Gene context of Autogel


Analytical, diagnostic and therapeutic context of Autogel


  1. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Wymenga, A.N., Eriksson, B., Salmela, P.I., Jacobsen, M.B., Van Cutsem, E.J., Fiasse, R.H., Välimäki, M.J., Renstrup, J., de Vries, E.G., Oberg, K.E. J. Clin. Oncol. (1999) [Pubmed]
  2. Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study. Mottet, C., Sieber, C.C., Nauer, A., Drewe, J., Fried, R., Larsen, F., Beglinger, C. Hepatology (1998) [Pubmed]
  3. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Ruszniewski, P., Ducreux, M., Chayvialle, J.A., Blumberg, J., Cloarec, D., Michel, H., Raymond, J.M., Dupas, J.L., Gouerou, H., Jian, R., Genestin, E., Bernades, P., Rougier, P. Gut (1996) [Pubmed]
  4. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Giusti, M., Ciccarelli, E., Dallabonzana, D., Delitala, G., Faglia, G., Liuzzi, A., Gussoni, G., Giordano Disem, G. Eur. J. Clin. Invest. (1997) [Pubmed]
  5. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Shimon, I., Yan, X., Taylor, J.E., Weiss, M.H., Culler, M.D., Melmed, S. J. Clin. Invest. (1997) [Pubmed]
  6. Lanreotide reduces serum free and total insulin-like growth factor-I after angioplasty. Frystyk, J., Skjaerbaek, C., Alexander, N., Emanuelsson, H., Suryapranata, H., Beyer, H., Foegh, M., Orskov, H. Circulation (1996) [Pubmed]
  7. Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors? Völter, V., Peschel, C. J. Clin. Oncol. (2004) [Pubmed]
  8. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. Colao, A., Pivonello, R., Auriemma, R.S., Briganti, F., Galdiero, M., Tortora, F., Caranci, F., Cirillo, S., Lombardi, G. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  9. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. Giusti, M., Gussoni, G., Cuttica, C.M., Giordano, G. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  10. Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis. Schiedermaier, P., Koch, L., Stoffel-Wagner, B., Layer, G., Sauerbruch, T. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  11. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Steffin, B., Gutt, B., Bidlingmaier, M., Dieterle, C., Oltmann, F., Schopohl, J. Eur. J. Endocrinol. (2006) [Pubmed]
  12. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Karavitaki, N., Botusan, I., Radian, S., Coculescu, M., Turner, H.E., Wass, J.A. Clin. Endocrinol. (Oxf) (2005) [Pubmed]
  13. Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers. Drewe, J., Sieber, C.C., Mottet, C., Wullschleger, C., Larsen, F., Beglinger, C. Clin. Pharmacol. Ther. (1999) [Pubmed]
  14. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. Danila, D.C., Haidar, J.N., Zhang, X., Katznelson, L., Culler, M.D., Klibanski, A. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  15. Effect of long-acting somatostatin analog (Somatulin) on renal hyperfiltration in patients with IDDM. Jacobs, M.L., Derkx, F.H., Stijnen, T., Lamberts, S.W., Weber, R.F. Diabetes Care (1997) [Pubmed]
  16. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion. Sieber, C.C., Beglinger, C., Bart, S., Tschoepl, M., Currie, G., Larsen, F., Drewe, J. Clin. Pharmacol. Ther. (2004) [Pubmed]
  17. Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. Häyry, P., Räisänen, A., Ustinov, J., Mennander, A., Paavonen, T. FASEB J. (1993) [Pubmed]
  18. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. Vitale, G., Tagliaferri, P., Caraglia, M., Rampone, E., Ciccarelli, A., Bianco, A.R., Abbruzzese, A., Lupoli, G. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  19. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. Zatelli, M.C., Maffei, P., Piccin, D., Martini, C., Rea, F., Rubello, D., Margutti, A., Culler, M.D., Sicolo, N., degli Uberti, E.C. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  20. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Hofland, L.J., van Koetsveld, P.M., Waaijers, M., Zuyderwijk, J., Lamberts, S.W. Endocrinology (1994) [Pubmed]
  21. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Florio, T., Thellung, S., Arena, S., Corsaro, A., Spaziante, R., Gussoni, G., Acuto, G., Giusti, M., Giordano, G., Schettini, G. Eur. J. Endocrinol. (1999) [Pubmed]
  22. Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment. Kaal, A., Orskov, H., Nielsen, S., Pedroncelli, A.M., Lancranjan, I., Marbach, P., Weeke, J. Eur. J. Endocrinol. (2000) [Pubmed]
  23. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide. Díez, J.J., Iglesias, P., Gómez-Pan, A. J. Endocrinol. Invest. (2001) [Pubmed]
  24. Labeling and quality control of 188Re-lanreotide. Verdera, S., Balter, H., Rodríguez, G., Oliver, P., Souto, B., López, A., Goncalvez, Z. Cell. Mol. Biol. (Noisy-le-grand) (2002) [Pubmed]
  25. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. Drange, M.R., Melmed, S. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  26. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Virgolini, I., Traub, T., Novotny, C., Leimer, M., Füger, B., Li, S.R., Patri, P., Pangerl, T., Angelberger, P., Raderer, M., Burggasser, G., Andreae, F., Kurtaran, A., Dudczak, R. Curr. Pharm. Des. (2002) [Pubmed]
  27. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Florio, T., Thellung, S., Corsaro, A., Bocca, L., Arena, S., Pattarozzi, A., Villa, V., Massa, A., Diana, F., Schettini, D., Barbieri, F., Ravetti, J.L., Spaziante, R., Giusti, M., Schettini, G. Clin. Endocrinol. (Oxf) (2003) [Pubmed]
  28. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicentre study. Soule, S., Conway, G., Hatfield, A., Jacobs, H. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
WikiGenes - Universities